Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

[Image: see text] GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this report, we present the discovery...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang, Yingcai, Liu, Jiwen (Jim), Dransfield, Paul J., Zhu, Liusheng, Wang, Zhongyu, Du, Xiaohui, Jiao, Xianyun, Su, Yongli, Li, An-rong, Brown, Sean P., Kasparian, Annie, Vimolratana, Marc, Yu, Ming, Pattaropong, Vatee, Houze, Jonathan B., Swaminath, Gayathri, Tran, Thanhvien, Nguyen, Khanh, Guo, Qi, Zhang, Jane, Zhuang, Run, Li, Frank, Miao, Lynn, Bartberger, Michael D., Correll, Tiffany L., Chow, David, Wong, Simon, Luo, Jian, Lin, Daniel C.-H., Medina, Julio C.
Format: Artigo
Language:Inglês
Published: American Chemical Society 2013
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027505/
https://ncbi.nlm.nih.gov/pubmed/24900707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml300427u
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items